Business Wire

Wick Hill and Zycko Become Part of Nuvias Group, the New Name for the pan-EMEA, High Value Distribution Business Being Built by Rigby Private Equity (RPE).

Del

Rigby Private Equity (RPE) announces the formation of Nuvias Group, a holding company for the pan-EMEA high value distribution business being built by RPE, to redefine specialist value distribution. Wick Hill and Zycko now become part of Nuvias Group and will be known as -

Wick Hill, a Nuvias group company

Zycko, a Nuvias group company

Nuvias strategy

With Nuvias, RPE is building an EMEA-wide, high-value, specialist distribution business, with a common proposition and consistent delivery. The strategy is to redefine value distribution to the channel, enabling the channel and vendor community to deliver exceptional business value to their customers and creating new standards of channel success.

Nuvias will provide a consistent quality of service, with best-in-class technologies, giving reseller partners local access to the best international services and solutions. Local expertise is backed up by a consistent operating platform, offering the highest level of value-added services and flexibility. For vendor partners and solution providers, Nuvias will deliver accelerated growth at all stages of the business and product growth lifecycle, enabling rapid expansion throughout EMEA.

Paul Eccleston, head of RPE, also now becomes CEO of Nuvias. He commented: “Zycko and Wick Hill form the foundations of Nuvias, a new type of international distribution company. We’re building a distributor to meet the evolving demands of the channel. As of today, Nuvias is already serving 40 vendors and 5,000 resellers in thirteen countries. Moving forward, we will be covering all major territories in EMEA, offering a common value proposition, consistently executed. This will give any vendor or reseller best in class distribution services, no matter in which country.”

Wick Hill and Zycko

Wick Hill and Zycko were the first acquisitions for RPE and now are the first high value, specialist distributors in Nuvias Group. Both companies are strong brands, with an exceptional reputation and a commitment to excellence. They both provide high value added services, with best-of-breed solutions that give channel partners good margins and consultancy opportunities. These philosophies and values are also core to Nuvias and will be fundamental as Nuvias continues to grow.

As far as vendors and resellers are concerned, there will be no changes, but there will certainly be additional opportunities for growth. Both Wick Hill and Zycko will carry on operating from their current sites, with existing staff, and headed up by Ian Kilpatrick, Wick Hill chairman, and David Galton-Fenzi, Zycko CEO.

Ian Kilpatrick, chairman Wick Hill Group, commented: “This is an exciting move in the growth and evolution of Wick Hill and Zycko. Having us operating separately under the Nuvias banner builds on the strength and reputation of both companies while providing us with a common identity for our expansion in EMEA.”

David Galton-Fenzi, CEO of Zycko, said: “There is a growing level of excitement and anticipation amongst our staff, customers and vendor partners, largely due to the growth and development possibilities that will arise in the future with Nuvias. For Zycko and Wick Hill staff, the creation of Nuvias will bring a new wave of opportunities that will create strong, medium and long term career paths for our people across EMEA. This, coupled with the speed of our expected growth, makes Nuvias a great place to build a successful career for the future.”

The new name acknowledges that in future there will be more high value-add, specialist distributor acquisitions, more countries added to the geographical scope, more services provided, as well as new vendor and reseller partner needs. So it makes sense to bring them all together under one joint Group name.

Today, the Nuvias product portfolio encompasses networking, infrastructure, security, communications, storage, continuity, recovery, access, performance, monitoring and management. Turnover is over US$ 300 million. Recently, Nuvias became a pan-EMEA distributor for vendors Unitrends and Malwarebytes. In January 2015, the first joint Wick Hill/Zycko office was opened in Vienna, Austria.

New board appointments

Ian Kilpatrick, David Galton-Fenzi, Lee Driscoll, Zycko’s chief sales officer, and Helge Scherff, managing director of Wick Hill Germany, all join the Nuvias board.

INFORMATION FOR EDITORS

Regional structure

The current geographical structure of Nuvias is divided into three regions, with offices in thirteen countries.

Northern

UK, Nordics and Benelux. This region is headed up by Lee Driscoll.

Central

DACH and Central Europe. This region is headed up by Helge Scherff.

Southern

France, Iberia, Italy and the Mediterranean. This region is headed up by David Galton-Fenzi, on an interim basis.

ENDS

Contact information

Wick Hill
Annabelle Brown
public relations consultant
01326 318212
email abpublicrelations@btinternet.com
Wick Hill https://www.wickhill.com
Zycko http://www.zycko.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i